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Mouse antisera against calf terminal deoxynucleotidyltransferase (terminal transferase) have been 
prepared. The sera have been used to characterize terminal transferase both by studying inhibition of 
enzyme activity and by developing a competition radioimmunoassay using highly purified ‘?labeled 
terminal transferase. By either assay, anti-terminal transferase serum did not cross-react significantly 
with calf DNA polymerases DI and p, Escherichia coli DNA polymerase I, or the reverse transcriptase of 
Moloney mouse leukemia virus. The calf terminal transferase did, however, share cross-reactive but not 
identical determinants with human and murine terminal transferase. The radioimmunoassay could 
detect as little as 2 ng of terminal transferase/mg of soluble protein in a tissue extract. Thymocytes were 
found to contain 280 ng of terminal transferase/mg of cell protein or about 1 x lo5 molecules/cell; bone 
marrow had about 1% of the level of enzyme found in thymus. Extracts of spleen, peripheral white blood 
cells, lymph nodes, liver, muscle, and kidney all lacked detectable antigenicity of terminal transferase. 
These data indicate that terminal transferase is a tissue-specific enzyme and is not related to other DNA 
polymerases. 
Terminal deoxynucleotidyltransferase (terminal transfer- 
ase) is an enzyme with the unique ability to polymerize 
deoxynucleotides onto a primer in the absence of a template 
(1). It has been purified to homogeneity and extensively 
characterized (1, 2). In humans (3), rats (4), and mice (5, 6), 
terminal transferase activity appears to be restricted to the 
thymus and bone marrow cells among various tissues exam- 
ined. The cells containing terminal transferase in the primary 
lymphoid organs have been partially characterized (3-6). The 
function of terminal transferase in the physiology of the 
thymus and bone marrow cells remains unknown, although it 
has been suggested that the enzyme might act as a somatic 
mutator in the generation of diversity (7). 
Our interest in terminal transferase originated from the 
discovery of the enzyme in the circulating leukemic cells of a 
patient with acute lymphoblastic leukemia (8). As part of our 
effort to improve the method of detecting terminal transferase, 
we have now developed a radioimmunoassay for the enzyme. 
With this assay the enzyme can be detected in the presence of 
inhibitors and accurately quantitated independent of the 
vagaries of enzymatic assay. In this communication we de- 
scribe the preparation and characterization of an antiserum 
made against calf terminal transferase. By using this anti- 
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serum and Y-labeled pure enzyme, a competition radioim- 
munoassay has been developed, and applied to study the 
antigenic relatedness of terminal transferase to other DNA 
polymerases and to quantitate terminal transferase in crude 
tissue extracts. 
EXPERIMENTAL PROCEDURE 
Methods 
Assay of DNA Polymerases-Eukaryotic DNA polymerases were 
named according to a system recently devised (9, 10). Templates, 
primers, and deoxynucleotide triphosphates were obtained from com- 
mercial sources (8). Standard reaction mixtures (100 ~1) contained 0.05 
M Tris-HCl (pH 8.3) and one of the following sets of reagents: (a) for 
terminal transferase assay: 2 pg of oligo(dA)/0.6 rnM M&1,/2 rnM 
dithiothreitoU450 pm01 of [3H]dGTP (2600 cpm/pmol); (b) for DNA 
polymerase 01 assay: 1 pg of poly(dCY0.5 Ng of poly(dI)/4 rnM 
magnesium acetate/450 pmol of [3H]dGTP (2600 cpm/pmol)/2 mM 
dithiothreitol; (c) for DNA polymerase p assay: 2 pg of poly(dA-dT)/ 6 
rnM magnesium acetate/2 rnM dithiothreito1/400 pmol of [IH]dTTP 
(2300 cpm/pmol)/ 20 nmol of dATP; (d) for DNA polymerase y assay: 1 
piof poly(rAV0.5 pg of oligo(dT)/0.8 mM mangan&eSchloridejlOO p&ml 
01 [3H]dTTP (2000 cpm/pmol); (e) for reverse transcriptase assays: 2 
Kg of poly(rC)/0.4 pg of oligo(dG)/6 mM magnesium chloride/2 rn~ 
dithiothreitoU450 pmol of ISHldGTP (2200 cpm/pmol). 
Enzyme Neutralization-Assay-Reaction- mixtures containing ap- 
propriate amounts of enzymes and antiserum in 70 ~1 of 0.1 M KC1/25 
mM Tris (pH 8.3)/20% glycerol/500 pg/ml of bovine serum albumin 
were incubated at 37” for 20 min (Incubation I). Then 30 ~1 of a 
concentrated reaction mixture containing substrates, primers, tem- 
plates, and metal ions optimal for each enzyme to be tested were 
added, and the reaction was allowed to proceed at 37” for another 20 
min (Incubation II). The assays were terminated by adding an equal 
volume of 20% trichloroacetic acid. 
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2400 Serology of Terminal Deoxynucleotidyltransferase 
Immunization--F:,(CBA/H-TGJ x SJL/J) female mice (8 weeks old) 
were injected intraperitoneally with 2 x lo8 heat-killed Bordetella 
pertussis organisms. Four hours later they were injected intraperitone- 
ally with 30 gg of the A-2 terminal transferase (see “Materials”), which 
had been preadsorbed to alum according to a published procedure (11). 
Schedules of antigen administration and bleeding were as described in 
the legend to Fig. 1. Mice were bled from the tail vein into glass tubes. 
After 10 hours at 4’, antisera were collected by centrifuging the clotted 
blood at 1,000 x g for 5 min and then stored at -70”. The antisera were 
used without further purification. Unless otherwise stated, the serum 
used for the experiments described here was the fifth or sixth bleeding 
from Animal 1. 
Purification of Terminal Transferase for Radioimmunoassay-Calf 
thymus glands (1.2 kg) with contaminating tissues removed were 
processed for terminal transferase purification according to the pub- 
lished method (2). The specific activity of the final purified enzyme 
was 4140 units/mg of protein, which represents at least a 4,000.fold 
purification from the crude thymic extracts (see Fig. 11). Over 98% of 
the protein of this preparation appears to be terminal transferase as 
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(Fig. 5). The purified terminal transferase was stored in 0.3 M 
potassium phosphate buffer, pH 7.2, at -70”. 
Iodination of Terminal Transferase-Protein iodination was carried 
out by the method of Greenwood et al. (12). Reaction mixtures (35 ~1 in 
0.3 M potassium phosphate buffer, pH 7.4) containing 2 Kg of purified 
terminal transferase, 500 rCi of Na’Y (585 mCi/ml) and 0.2 pg of 
chloramine-T were incubated for 3 min in an ice bath. The iodinated 
calf terminal transferase was separated from free Nalz51 by gel 
chromatography on a Sephadex G-25 column (0.5 x 15 cm) equili- 
brated with 0.3 M potassium phosphate buffer, pH 7.2. The ‘Y-termi- 
nal transferase was further purified on a Sephadex G-75 column (1.5 x 
100 cm) equilibrated with 0.3 M potassium phosphate buffer, pH 
7.2/10 @g/ml of bovine serum albumin/O.Ol% Triton X-100 (Buffer A). 
The specific activity of ‘ZSI-terminal transferase was 2.5 to 5 x lo3 
cpm/ng. The iodinated enzyme co-chromatographed with native calf 
terminal transferase on a Sephadex G-75 column, indicating no gross 
change in enzyme aggregation after its iodination. 
Radioimmunoassay for Terminal Transferase-The mouse anti-ter- 
minal transferase was titrated as described by Panet et al. (13). Then 3 
~1 of normal mouse serum plus 5 ~1 of mouse anti-terminal transferase 
serum (diluted in Buffer A containing 1 mg/ml of bovine serum 
albumin) were added to tubes in quantity sufficient to precipitate 
about 50% of the input Y-terminal transferase. Additional compo- 
nents were added in the following sequence: the unknown sample, 
“4-terminal transferase (2 to 4 ng), goat anti-mouse IgG’ (30 ~1 
containing 2 rnM EDTA). After each addition the reaction tube was 
incubated at 37” for 1 hour, then at 4’ for 6 hours more. Final reaction 
volume was 230 ~1. The final immunoprecipitate was collected by 
centrifugation at 3,000 x g, washed two times with Buffer A, and 
counted in a y spectrometer. In competition radioimmunoassay 100% 
precipitation represents the amount of ‘2SI-terminal transferase precip- 
itated in the absence of any competing antigen. 
Preparation of Cellular Extract for Radioimmunoassay-Tissues in 
4 volumes of Buffer B (0.2 M potassium phosphate, pH 7.2/l rnM 
EDTA/l mM mercaptoethanol/5% ethanol/2 mM phenylmethylsul- 
fonylfluoride) were homogenized in a Waring Blendor at high setting 
for 2 min at 4’. After adding Triton X-100 to a final concentration of 
0.5?), the homogenates were stirred at 4” for another 2 hours, and then 
centrifuged at 10,000 x g for 10 min. The supernatant was extracted 
with 5 volumes of ether three times, and dialyzed three times against 
100 volumes of Buffer C (0.3 M potassium phosphate, pH 7.2/0.01% 
Triton X-100/0.5 mM EDTA/l mM mercaptoethanol). The extract was 
then centrifuged at 100,000 x g for 60 min and the supernatant was 
used for radioimmunoassay. When cells were used as the starting 
materials, they were homogenized in a tightly fitted Dounce glass 
homogenizer and processed in a manner identical to that described 
above. 
Miscellaneous Methods-Amounts of protein were determined by 
the method of Lowry et al. (14) using bovine serum albumin as 
standard. Analyses by sodium dodecyl sulfaate-polyacrylamide gel 
electrophoresis were performed according to Laemmli (15). 
Materials 
Enzyme Preparations-Mouse and human terminal transferases 
were partially purified as described in earlier reports (3, 5). Moloney 
’ The abbreviation used is: IgG, immunoglobin G. 
mouse leukemia virus reverse transcriptase was purified to homoge- 
neity (16). Calf DNA polymerase 01 (12,400 units/mg, containing 10 to 
30% enzyme protein), and calf DNA polymerase /3 (110,000 units/mg, 
containing 50% enzyme protein) were kindly provided by Dr. L. M. S. 
Chang, University of Connecticut Medical Center. Escherichia coli 
DNA polymerase I was a generous gift of Dr. A. Kornberg, Stanford 
University. Fresh calf thymus glands were purchased from Trelegan 
Co., Cambridge, Mass. 
Antigen for Immunization-Two lots of calf terminal transferase 
(Lot A-2, 2117 units/mg; Lot 3363, 331 units/mg* purchased from the 
P-L Biochemical Inc., were screened for their use as antigen. The 
enzymes were prepared according to Chang and Bollum (2). Lot A-2 
was further characterized because of its higher specific activity. 
Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
showed that A-2 protein contains two major bands corresponding to the 
two subunits of calf terminal transferase as described by Chang and 
Bollum (2). Later analysis of A-2 protein by the radioimmunoassay 
(Fig. 8) indicated that about 60% of its total protein was terminal 
transferase. No contaminating enzyme activities of DNA polymerase 
a, /3, and y were detected in Lot A-2. Because a monospecific 
antiserum is not a necessary requirement for the development of a 
radioimmunoassay, the A-2 protein was considered acceptable for use 
as an antigen for immunization. 
Reagents-Goat anti-mouse IgG was a product of Meloy Laboratory, 
Springfield, Virginia. Na lZsI (585 mCi/ml, > 14 mCi/pg) was purchased 
from Amersham/Searle, Arlington Heights, Ill. Sephadex G-25, G-75. 
and G-100 were obtained from Pharmacia Fine Chemicals, Inc., 
Piscataway, N. J. Electrophoretically pure bovine serum albumin was 
purchased from Calbiochem, San Diego, Calif. 
RESULTS 
Immunization and Characterization of Antisera 
To study the response of mice injected with terminal trans- 
ferase, serum from injected mice was collected at various times 
and assayed for its ability to neutralize the enzymatic ac- 
tivity of terminal transferase. The immune response of two 
animals is shown in Fig. 1. Neutralizing activity in the sera 
could be detected 1 week after the second antigen injection. 
Activity was maximal by 12 days after the second injection 
and was maintained by a third injection. In mouse 2 the ac- 
tivity dropped markedly thereafter, while in mouse 1 it stayed 
at a high level for at least 100 days. 
To determine whether the neutralizing activity of the serum 
was due to immunoglobulin, the ability of goat anti-mouse 
IgG to precipitate the inhibiting factor was tested. For this 
experiment, normal mouse serum and the mouse anti-terminal 
transferase serum were incubated with goat anti-mouse IgG 
and then centrifuged to remove the precipitate. The ability of 
the treated mouse sera to inhibit terminal transferase was then 
compared to that of sera that had not been treated with goat 
anti-mouse IgG (Table I). The goat serum by itself inhibited 
terminal transferase about 50%; the inhibition is presumably 
not due to anti-terminal transferase activity because the goat 
’ One enzyme unit is the amount of enzyme that incorporates 1 nmol 
of dGMP onto an oligo(dA) primer during 1 hour at 37”. Enzyme 
assays for terminal transferase in this report, unless otherwise stated, 
were done in a Tris-buffered system as described in “Methods.” In the 
literature, terminal transferase assay has often been carried out in a 
cacodylate-buffered system (0.2 M potassium cacodylate, pH 7.2; 4 mM 
MgCl,; 1 mM 2-mercaptoethanol; 10 mM d(pT),; and 1 TIM dATP; see 
Ref. 2). For the same amount of purified terminal transferase, a much 
higher enzyme activity can apparently be obtained in the cacodylate- 
buffered system than in the Tris-buffered system. For example, a 
batch of calf terminal transferase (the enzyme was a gift from Dr. 
Robert L. Ratliff of the Los Alamos Laboratory, New Mexico) which 
had a specific activity of 32,700 units/mg assayed in the cacodylate 
buffered system, turned out to be 1260.5 units/mg assayed in the 
Tris-buffered system. The ratio of the sensitivity of the two enzyme 
assays is therefore 26. We continue to use the Tris system because we 
have been thus far unable to reproduce the higher literature values 
using cacodylate. 
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Serology of Terminal Deoxynucleotidyltransferase 2401 
30 60 so 
Days after first antigen injection Muwtes of incubation Nanograms of calf terminal transferose 
FIG. 1 (left). Immune response monitored by enzyme neutralization 
assay. Two animals were injected with terminal transferase at Day 0 
and reinjected at the time indicated by the arrows. At various times 
the mice were bled and the anti-terminal transferase titer of the serum 
was studied. Portions of 0.12 unit (40 ng) of calf terminal transferase 
were incubated with antisera (final dilution l/150). The neutralization 
assays were carried out as described under “Methods.” O---O, 
Mouse 1; 0- - -0, Mouse 2. 
FIG. 2 (center). Kinetics of enzyme neutralization by antiserum. 
Portions of 40 ng (0.12 unit) of calf terminal transferase were incubated 
at 37” with 31.2 pg of antiserum protein (final antiserum dilution 
l/140) or an equivalent amount of normal mouse serum protein. 
Samples were withdrawn at desired intervals and frozen in acetone/dry 
ice bath. After the last time point, all samples were thawed and 
TABLE I 
Nature of Enzyme Neutralization Factor in Mouse Antiserum 
Where indicated, mouse sera (2 ~1 in 18 ~1 of 140 rnM NaC1/5 rnM 
KC1/16 rnM Na,HPOJ3 mM KH,PO,, pH 7.4) were incubated with or 
without 20 ~1 of goat anti-mouse IgG (53.8 mg/ml) at 37” for 1 hour, 
then at 4” overnight. At the end of incubation, reaction mixtures were 
centrifuged at 10,000 x g for 10 min. Supernatants (10 ~1) were tested 
for neutralization activity against 0.11 unit of terminal transferase as 
described under “Methods.” 
Addition Enzyme activity Inhibition 
None 
Normal mouse serum 
Mouse anti-terminal transferase 
Goat anti-mouse IgG 
Goat anti-mouse IgG plus normal 
mouse serum 
Goat anti-mouse IgG plus mouse 
anti-terminal transferase 
pmol dGMP 
incorporated 
218 
213.7 
3.6 
104 
108 
106.2 
90 
6.6 
98.3 
52.3 
50.5 
51.3 
serum could not precipitate lZ51-terminal transferase (See Fig. 
6). In spite of the inhibitory activity of the goat serum, its abil- 
ity to precipitate the terminal transferase-neutralizing activity 
of the mouse antiserum is evident (Table I), and therefore the 
neutralizing factor must be immunoglobulin. 
Properties of Enzyme Neutralization Reaction 
The kinetics of enzyme neutralization by the mouse anti- 
terminal transferase serum are shown in Fig. 2. Inhibition was 
maximal after incubating terminal transferase with the mouse 
antiserum at 37” for 20 min. 
A titration of increasing amounts of terminal transferase 
against fixed amounts of antisera is shown in Fig. 3. At l/1000 
dilution (4.2 pg of antiserum proteins), the more antigen 
added, the less inhibition was observed. 
mixtures (30 ~1) containing reaction reagents added. The enzymatic 
reaction was allowed to proceed at 37” for 20 min (see “Methods”). 
Only 20% of the terminal transferase activity was neutralized during 
the 20.min incubation for enzymatic assay (see zero time point). 
Enzyme activity measured in the absence of any serum protein was 
taken as 100%. 04, immune serum; O----O, normal serum. 
FIG. 3 (right). Titration of fixed amounts of antiserum against 
increasing amounts of calf terminal transferase. Neutralization mix- 
tures were established under “Methods,” containing 4.2 pg of nonim- 
mune or immune antiserum protein (l/100 final antiserum dilution) 
and serial dilutions of calf terminal transferase. The ratio of enzyme 
activity after treatment with immune or nonimmune serum was used 
to compute the percentage of enzyme inhibition. 
A titration of increasing amounts of immune sera against 
fixed amounts of terminal transferase is shown in Fig. 4 (A). 
The enzyme was preincubated with the antiserum prior to the 
determination of residual enzyme activity. The enzyme activity 
of 40 ng of terminal transferase was reduced to 50% of control 
at 5.4 pg of antiserum protein (l/800 antiserum dilution). 
Specificity of Antiserum 
By enzyme neutralization assay, the antiserum did not 
appear to significantly inhibit calf DNA polymerases cy and p, 
Escherichia coli DNA polymerase I, or reverse transcriptase 
from Moloney mouse leukemia virus (Fig. 4). It did, however, 
inhibit human and, less extensively, murine terminal transfer- 
ase. Even using less human or mouse terminal transferase than 
the amount of calf terminal transferase used, much more 
antiserum was needed to achieve the same degree of inhibition 
with heterologous terminal transferase than with the calf 
enzyme. 
Radioimmunoassay 
Preparation of Labeled Enzyme-For radioimmunoassay, 
the enzyme used for iodination should be of the highest purity. 
We prepared terminal transferase from calf thymus for this 
purpose (see “Methods”). The preparation had a specific 
activity of 4140 units/mg and represented at least a 4000.fold 
purification as determined by radioimmunoassay (see Fig. 11). 
Analysis by sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis indicated that greater than 95% of protein in this 
preparation was contained in the two subunits of terminal 
transferase (Fig. 5). The molecular weight of the large subunit 
is 28,000, and that of the small subunit is 8,000. After 
iodination, the majority of the “‘1 was contained in the two 
terminal transferase bands (Fig. 5). Much of the “‘1 not in the 
terminal transferase was not immunoprecipitable-the lZ51 in 
the immunoprecipitate was virtually all in the terminal 
transferase bands (Fig. 5). 
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2402 Serology of Terminal Deoxynucleotidyltransferase 
Mwogroms of ontlserum proten 
FIG. 4. Effect of increasing amounts of anti-terminal transferase 
serum on the activity of various DNA polymerases. Neutralization 
mixtures were established as described under “Methods.” They con- 
tained either 0.06 unit of human or mouse terminal transferase, 0.12 
unit of calf terminal transferase, 0.05 unit of calf DNA polymerase 
LY and p, or 0.1 unit of Moloney mouse leukemia virus reverse transcrip- 
tase (final antiserum dilution, l/800). The enzyme activity in the pres- 
ence of immune protein is expressed as a percentage of the activity 
in the presence of identical amounts of nonimmune serum protein. 
A-A, calf terminal transferase; O-O, human terminal transfer- 
ase; x -x, mouse terminal transferase; O-O, calf DNA polymer- 
ase 01; m-m, calf DNA polymerase fl; 04, reverse transcriptase 
of Moloney mouse leukemia virus. 
0 0 0 
-Origin 
-26.000 
-12,000 
- Dye 
FIG. 5. Analysis of the purified calf terminal transferase by electro- 
phoresis through sodium dodecyl sulfate-polyacrylamide gel. 1, en- 
zyme (20 yg) was submitted to electrophoresis and then stained with 
Coomassie blue. 2, ‘2sI-terminal transferase (25,000 cpm) preparation 
was submitted to electrophoresis and then the gel was developed by 
autoradiography. 3, ‘2sI-terminal transferase (22,000 cpm) was precipi- 
tated by antiserum as described under “Methods.” The precipitate 
was submitted to electrophoresis and developed by autoradiography. 
Molecular weights of markers analyzed on a parallel gel: bovine serum 
albumin, 68,000; ovalbumin, 43,000; chymotrypsinogen, 26,000; cyto- 
chrome c 12,500. The concentrations of all three gels were 12.5%. 
Immunoprecipitation of Y-terminal Transferase and Its 
Inhibition-The capacity of various antiserum dilutions to 
precipitate ‘Y-terminal transferase is shown in Fig. 6. With 
high antiserum concentration, 90% of the labeled enzyme was 
immunoprecipitable (if the Sephadex G-75 column chromatog- 
raphy of the iodinated enzyme was omitted, 75 to 80% was 
precipitable). Preimmune serum from the same animal that 
produced the antiserum precipitated less than 2% of the 
labeled enzyme. 
Reciprocal of serum dilution 
Immunoprecipitation of ‘251-calf terminal transferase by 
varying concentrations of antiserum. Reaction was carried out essen- 
tially as described by Panet et al. (13) except using Buffer A. Either 
anti-terminal transferase serum (0-O) or the preimmune serum 
from the same mouse (04) were used. Input lZsI-terminal transfer- 
ase, 7,000 cpm. 
The immune response of the two mice to injected antigens 
was quantitated by radioimmunoassay (Fig. 7). It was very 
similar to that obtained by enzyme neutralization assay 
(compare to Fig. 1). 
To establish a competition radioimmunoassay, from the 
data of Fig. 6 an amount of antiserum was determined that 
would precipitate 50% of the labeled enzyme. Competition of 
this precipitation was studied by incubating increasing 
amounts of unlabeled enzyme with the antiserum before using 
it to precipitate ‘Y-terminal transferase. With this system, 
about 5 ng of terminal transferase could be detected, an 
amount of enzyme that displaced 10% of the labeled terminal 
transferase (Fig. 8). 
Comparison of Enzyme Purity by Radioimmunoassay-The 
terminal transferase preparation used to elicit the mouse 
anti-terminal transferase serum was compared for purity with 
the highly purified terminal transferase used for radioiodina- 
tion. To compete 20% of the ‘Y-labeled terminal transferase 
required 8 ng of the highly pure terminal transferase and 13 ng 
of the preparation used as antigen (Fig. 8). This difference 
agrees well with the approximately 2-fold higher specific 
activity of the purer terminal transferase preparation and 
demonstrates the ability of radioimmunoassay to monitor 
enzyme purity. 
Specificity of Assay-The ability of heterologous terminal 
transferase and other DNA polymerases to compete with the 
labeled calf terminal transferase was investigated. Calf termi- 
nal transferase did not appear to cross-react with E. coli DNA 
polymerase I, Moloney mouse leukemia virus reverse tran- 
scriptase, or calf thymus DNA polymerases o( and @ (Fig. 9). 
The preparation of calf DNA polymerase 01 was found to be 
contaminated with terminal transferase (0.5% of total protein) 
as determined by enzyme assay. The data presented here have 
been corrected for this contamination. 
Human and murine terminal transferase did compete with 
the ‘251-terminal transferase (Fig. 10). The slopes of the 
radioimmunoassay competition curves for homologous and 
heterologous terminal transferase were quite distinct, however, 
indicating that the determinants recognized by the mouse 
antiserum on the calf enzyme are represented on human and 
mouse terminal transferase in a modified form. The apparent 
distant relatedness of murine terminal transferase with calf 
enzyme might be a result of the fact that the antiserum was 
elicited in the mouse. 
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Serology of Terminal Deoxynucleotidyltransferase 2403 
I I 
60 100 
Days after first antigen InjectIan 
FIG. 7. Titer of the antisera determined by radioimmunoassay. 
Immunoprecipitation of ‘2SI-terminal transferase (7,000 cpm) was 
conducted as described under “Methods.” The final dilution of all 
antisera tested was l/750. 
F 
3; 0 I I I I 
0.1 I IO 100 
Nanograms (ng) of competing protein 
FIG. 8. Competition radioimmunoassay. Immunoprecipitation of 
‘Y-terminal transferase was competed by increasing amounts of either 
unlabeled calf terminal transferase (Lot A-2 used for immunization) 
(a- - -0) or purified terminal transferase (2X7’) (O-O). The 
final concentration of the antiserum was l/1000, which gave 45% 
precipitation of input ‘Y-terminal transferase (6500 cpm). 
Tissue Distribution of Terminal Transferase-The presence 
of terminal transferase among various calf tissues was studied 
by radioimmunoassay. As shown in Fig. 11, the antigenic 
determinants of terminal transferase could only be detected in 
the thymus and bone marrow. Comparing the curve for pure 
terminal transferase with the curve for thymus, we estimate 
about 280 ng of terminal transferase/mg of soluble cell protein. 
Bone marrow would have about 1% of the terminal transferase 
concentration of thymus. The terminal transferase concentra- 
tion in negative tissues (spleen, lymph nodes, liver, muscle, 
white cells from peripheral blood, and kidney) must be lower 
than 2 ng of terminal transferase/mg of protein, or less than 
0.7% as much as that of the thymus. Mixing extracts of 
negative tissues with thymus extracts produced no masking of 
the terminal transferase in thymus, indicating that the nega- 
tive tissues truly lack terminal transferase. 
DISCUSSION 
The ability to elicit antibodies to terminal transferase has 
allowed us to study the antigenic sites on the enzyme using two 
different assays, inhibition of enzymatic activity and precipita- 
tion of labeled enzyme. The two types of assays give similar 
pictures: terminal transferase appears to be a unique enzyme, 
unrelated antigenically to other DNA polymerases. Terminal 
transferases from different animal species share antigenic 
Nanograms (ng) of competing protein 
FIG. 9. Determination of antiserum cross-reactivity with other 
DNA polymerases by competition radioimmunoassay. The preparation 
of calf DNA polymerase 01 containing 10 to 30% enzyme protein had a 
specific activity of 2400 units/mg. The preparation of calf DNA 
polymerase @ containing 50 to 60% enzyme protein had a specific 
activity of 110,000 units/mg. Escherichia coli DNA polymerase I (E. 
coli pal I) and reverse transcriptase of Moloney leukemia virus 
(MuLV-RT) were homogeneous enzymes. The final dilution of the 
antiserum was l/1000 which precipitated 48% of the input 1Z51-calf 
terminal transferase (T0) (6,000 cpm). 
s 
k I I I I I I 
Enzyme units of terminal transferases 
FIG. 10. Antiserum cross-reactivity with heterologous terminal 
transferase. Human and murine terminal transferase were partially 
purified as described under “Materials.” The amounts of enzyme 
added were determined from their specific activity. Final concentra- 
tion of antiserum was l/1000 which precipitated 45% of the input 
124-terminal transferase (TdZ’J (6,500 cpm). 
z: 
i 
‘1) 
0 I I 
IO 100 1000 10.000 
Micrograms (pg) of competing protein 
FIG. 11. Tissue distribution of calf terminal transferase. Preparation 
of cellular extracts was as described under “Methods.” Details of the 
assay were the same as in Fig. 10. Other negative tissues included 
lymph nodes, muscle, liver, and kidney. 
determinants, but the cross-reactions are fairly weak. Only 
tissues that have previously shown terminal transferase by 
enzymatic assay, specifically bone marrow and thymus (I, 6) 
have detectable antigenicity of terminal transferase by compe- 
tition radioimmunoassay. 
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2404 Serology of Terminal Deoxynucleotidyltransferase 
The antigenic uniqueness of terminal transferase relative to 
other types of DNA polymerases strengthens the concept that 
terminal transferase is an individual enzyme and not a subunit 
of a known DNA polymerase. Previous work showing that a 
rabbit antiserum against calf DNA polymerase (Y would not 
inhibit calf terminal transferase activity (17) also indicated the 
uniqueness of the enzyme. Furthermore, the restricted tissue 
distribution of terminal transferase, first recognized by Chang 
(18), argues against its being a subunit of a widely distributed 
enzyme such as DNA polymerase 01, p, or y. 
Using the mouse antisera and ‘2”I-labeled pure enzyme a 
radioimmunoassay for calf terminal transferase was developed 
that could detect less than 5 ng of the enyme (Fig. 8). This 
level of sensitivity is comparable with that of radioimmunoas- 
says used to quantitate reverse transcriptase and other viral 
proteins (13, 19, 20). With this assay, antigens related to 
terminal transferase could only be detected in the thymus and 
bone marrow cells. The level of the enzyme in the thymus is 
about 280 ng of terminal transferase/mg of soluble protein, 
which is about 3.5 times higher than the minimum value 
estimated by Chang and Bollum (2). On the basis of recovery of 
enzymatic activity, they determined that there is a minimum 
of 83.5 ng of terminal transferase/mg of protein in the calf 
thymus. The difference between their estimation and ours is 
probably a result of the different methods used. The level of 
terminal transferase in the calf bone marrow is about loo-fold 
lower than in the thymus. The magnitude of this difference 
between marrow and thymus is greater than previously found 
in the mouse by enzymatic assay (5). No molecules related to 
terminal transferase were found in the spleen, lymph nodes, 
liver, muscle, kidney, and white blood cells from peripheral 
blood. The limit of sensitivity of their detection was about 2 ng 
of terminal transferase/mg of protein. 
The number of terminal transferase molecules per thymo- 
cyte can be estimated from this data. We find about 19.2 mg of 
soluble protein per lo9 thymocytes; at 280 ng of terminal 
transferase/mg of protein, lo9 thymocytes should therefore 
have 5.3 pg of terminal transferase. Terminal transferase has a 
molecular weight of about 36,000 (a), so there are more than 1 
x lo5 molecules of terminal transferase per thymocyte. If 
terminal transferase has a role as a somatic mutator (6, 7), or 
as a modifier of cell DNA in any way, there is a large enough 
amount of enzyme present to cause very significant modifica- 
tion. 
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